Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Therapeutic Resistance To Anti Hormonal Drugs In Breast Cancer
Download Therapeutic Resistance To Anti Hormonal Drugs In Breast Cancer full books in PDF, epub, and Kindle. Read online Therapeutic Resistance To Anti Hormonal Drugs In Breast Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer by : Stephen Hiscox
Download or read book Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer written by Stephen Hiscox and published by Springer Science & Business Media. This book was released on 2009-01-11 with total page 202 pages. Available in PDF, EPUB and Kindle. Book excerpt: One of the main causes of failure in the treatment of breast cancer is the intrinsic presence of, or development of, drug resistance by the cancer cells. Recent studies on the mechanisms of cancer drug resistance have yielded important information highlighting both how tumour cells may escape these therapeutic constraints and that drug resistance may further impinge on tumour cell functions that may ultimately promote an adverse cell phenotype. New targets have been identified with potential therapeutic applications in resistant breast cancer leading to the subsequent evaluation of inhibitors of these targets in preclinical studies. Importantly, there is increasing evidence from such studies demonstrating the benefit of novel combination strategies as potential avenues for future drug regimens. Written by experts in the subject area, this book covers the molecular details and functional consequences of endocrine resistance in breast cancer with particular emphasis on the future applications of novel drug combinations that may be utilized to circumvent resistance and improve anti-tumour effects. This book represents a timely publication in the field of breast cancer research, providing current knowledge in the area of drug resistance and will be important reading material for clinicians and researchers alike.
Book Synopsis Endocrine Therapy in Breast Cancer by : William R. Miller
Download or read book Endocrine Therapy in Breast Cancer written by William R. Miller and published by CRC Press. This book was released on 2002-03-08 with total page 395 pages. Available in PDF, EPUB and Kindle. Book excerpt: This reference evaluates and describes the latest strategies for hormone suppression and blockade in the management of early and advanced stage breast cancer and explores the effects of tamoxifen, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and their combination on both breast cancers and normal tissues. Endocrine T
Book Synopsis Targeted Therapies in Breast Cancer by : Gw Sledge
Download or read book Targeted Therapies in Breast Cancer written by Gw Sledge and published by Clinical Pub. This book was released on 2012-06 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Book Synopsis Molecular Mechanisms of Drug Resistance And Strategies of Sensitization in Breast Cancer, 2nd edition by : Yan Cheng
Download or read book Molecular Mechanisms of Drug Resistance And Strategies of Sensitization in Breast Cancer, 2nd edition written by Yan Cheng and published by Frontiers Media SA. This book was released on 2024-01-11 with total page 198 pages. Available in PDF, EPUB and Kindle. Book excerpt: Basic scientific background Breast cancer is one of the most common cancer and the most frequent cause of cancer death among women worldwide. Currently, subtyping breast cancers into hormone receptor (HR) positive, human epidermal growth factor receptor-2 overexpressing (HER2+), and triple negative breast cancer (TNBC) is the basis of diagnosing and treating this disease. The main treatment strategies for breast cancer include surgery, endocrine therapy, molecular targeted therapy, chemotherapy, radiotherapy, immunotherapy and gene therapy. However, resistance of breast cancer cells to chemotherapeutic agents, molecular targeted therapies and immunotherapy may occur either intrinsically or de nova, and is often ultimately responsible for treatment failure. Therefore, drug resistance poses a major challenge to breast cancer treatment. Current developments: Drug resistance in breast cancer is a complex clinical condition originating from a wide range of molecular alterations. The development of endocrine therapy resistance is believed to be associated with many cellular changes, such as ESR1 gene mutations, bypassing estrogen signaling pathway and altered tamoxifen metabolism. Meanwhile, changes in immune response, alternation of drug-binding property and downstream pathways are involved in the mechanisms of drug resistance in HER2+ breast cancer. In addition, resistance to chemotherapeutic agents predominantly arises from increased drug efflux and cross resistance. Current studies suggest that treatment strategies and therapeutics have to be designed specifically to each patient in different clinical situations. The use of modern genomic, proteomic and functional analytical techniques has contributed to identify novel genes and signaling networks involved in breast cancer drug resistance. Moreover, the use of high-throughput techniques in combination with bioinformatics and systems biology approaches has aided the interrogation of clinical samples and allowed the identification of molecular signatures and genotypes that predict responses to certain drugs. Despite much progress has been made in the field of breast cancer drug resistance, such as combination therapy and drug-loaded nanoparticles, the complexity and variability of drug resistance mechanism still inevitably lead to the continuous occurrence of drug resistance. Therefore, with the increasing amounts of anti-breast cancer agents, there are now unprecedented opportunities to understand and overcome drug resistance through further research into mechanisms and corresponding strategies, which will help achieve lasting disease control and bring survival benefits to patients with advanced cancer. Papers of interest: The current Research Topic of Frontiers in Pharmacology focuses on publishing Original Research, Review articles and Case Reports focusing on (a) elucidating mechanisms of drug resistance in breast cancer, target mutations, tumor microenvironment, undiscovered genes and signaling pathways; (b) promising drug delivery systems that can enhance the sensitivity of anti- breast cancer agents to various tumors; (c) strategies that can improve patient care during bio-chemotherapeutic treatments; (d) small molecule compounds that are effective against drug-resistant breast tumors (e) biomarkers of chemotherapy resistance in breast cancer patients and (f) in vitro and in vivo models. Guidelines for article of submission: - Authors must stick to the set guidelines for ethical practices by the Frontiers journals. - The main content of the article must have certain innovation and research significance. - The authors should describe the construction method of drug-resistant cell lines when using them for experiments in the article.
Book Synopsis Overcoming Breast Cancer Therapy Resistance by : Zodwa Dlamini
Download or read book Overcoming Breast Cancer Therapy Resistance written by Zodwa Dlamini and published by Springer Nature. This book was released on with total page 390 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Drug and Hormonal Resistance in Breast Cancer by : Robert Brent Dickson
Download or read book Drug and Hormonal Resistance in Breast Cancer written by Robert Brent Dickson and published by Prentice Hall PTR. This book was released on 1995 with total page 474 pages. Available in PDF, EPUB and Kindle. Book excerpt: Featuring contributions from expert authors of international standing, this book explores emerging studies on the success and/or failure of chemotherapy in breast cancer. Covers the clinical resistance of breast cancer to treatment; chemo-hormonal reactions; anti-hormonal resistance; multidrug resistance; and fu/antimetabolites. For cancer and hormonal researchers and development scientists in pharmaceuticals and biomedicine. Previously announced in 7/93 PTR Catalog.
Book Synopsis Resistance to Aromatase Inhibitors in Breast Cancer by : Alexey Larionov
Download or read book Resistance to Aromatase Inhibitors in Breast Cancer written by Alexey Larionov and published by Springer. This book was released on 2015-04-25 with total page 298 pages. Available in PDF, EPUB and Kindle. Book excerpt: Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, including molecular mechanisms and translational aspects of drug resistance in AIs. Topics covered include research, experimental , and clinical data specifically focused on AI resistance in breast cancer. The volume will include three sections. The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure and function of aromatase protein. The second section provides the detailed mechanisms of resistance to AIs, while the third section explores prediction of resistance and potential strategies to overcome resistance. Breast cancer is the most common female cancer and AIs significantly improve treatments outcomes compatibly to previously used endocrine treatments. However 10-15% of post-operative patients develop a relapse during adjuvant treatment with AIs; about 25-50% of the patients do not respond to AIs in neo-adjuvant or metastatic setting, and the majority of metastatic patients who initially respond develop resistance within 3 years. There is an important need to understand these mechanisms of resistance in order to develop methods of preventing or overcoming the resistance to AIs, which will ensure a more successful outcome in treating breast cancer.
Download or read book Tamoxifen written by Philipp Y. Maximov and published by Springer Science & Business Media. This book was released on 2013-07-23 with total page 218 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
Book Synopsis Tamoxifen and Breast Cancer by : Michael W. DeGregorio
Download or read book Tamoxifen and Breast Cancer written by Michael W. DeGregorio and published by Yale University Press. This book was released on 1999-01-01 with total page 132 pages. Available in PDF, EPUB and Kindle. Book excerpt: A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. This edition contains information on developments in the use of tamoxifen, especially in the results of the Breast Cancer Prevention Trial.
Book Synopsis Clinical and Molecular Evaluation of Anti-estrogen Therapy Resistance in Breast Cancer by : Karin Johanna Beelen
Download or read book Clinical and Molecular Evaluation of Anti-estrogen Therapy Resistance in Breast Cancer written by Karin Johanna Beelen and published by . This book was released on 2014 with total page 266 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Tamoxifen Resistance in Breast Cancer Therapy by : Douglas M. Wolf
Download or read book Tamoxifen Resistance in Breast Cancer Therapy written by Douglas M. Wolf and published by . This book was released on 1993 with total page 466 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Tamoxifen written by John A. Kellen and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 383 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tamoxifen has persisted as a widely accepted and administered drug for almost 25 years. Following the many scientific papers and books on the subject, it has remained a very intriguing substance. This, perhaps, is the reason for another monograph on Tamoxifen. It is regrettably true that overviews, even when up to date after exhaustive research - the shibboleth of our cultures -, rapidly lose relevance with the passage of time. Scientists can sometimes be pictured as deep sea divers, who plunge into the unknown in search of a hitherto unknown world. Their descent is exciting, but eventually they must come up for air and integrate their experiences with others who also had to resurface. This book intends to collect and, where possible, to collate recent, but sometimes seemingly unrelated information. To quote Stephane Mallarme: "Everything in the world exists to end up in a book". Even if this is a tad cynical, it might not be far from the truth. If a little knowledge is a dangerous commodity, one can also add - tongue in cheek - that a vast amount of knowledge can be truly hazardous. It is likely that what might seem as entangled data is confusing, especially for those satisfied with the comfortable interpretation of Tamoxifen as an antiestrogen which has long been found insufficient. The complexity of its mechanisms and effects defies simple explanations and may even seem capricious, but only because of our ignorance.
Book Synopsis Estrogen/antiestrogen Action and Breast Cancer Therapy by : Virgil Craig Jordan
Download or read book Estrogen/antiestrogen Action and Breast Cancer Therapy written by Virgil Craig Jordan and published by Univ of Wisconsin Press. This book was released on 1986 with total page 564 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book marks one of the achievements of the "Estrogen and Antiestrogen Action: Basic and Clinical Aspects" Wisconsin Clinical Cancer Center conference in June 1984. It is not intended to be a recount of the meeting proceedings but is, rather, a historical review of the development of this field of endeavor during the past 30 years. The chapters have been written by many of the leading experts in the field who were asked to recount the development of a particular area or laboratory idea in which they had been personally involved. The book is intended to provide both scientists and clinicians with a single-volume overview of both the basic principles of hormonal control of breast cancer and the recent clinical results from cooperative groups around the world.
Book Synopsis Molecular Basis of Anti-hormonal Treatment and Resistance in Breast Cancer by : Mahta Mazaheri
Download or read book Molecular Basis of Anti-hormonal Treatment and Resistance in Breast Cancer written by Mahta Mazaheri and published by . This book was released on 2009 with total page 136 pages. Available in PDF, EPUB and Kindle. Book excerpt: Breast cancer is the most common type of malignancy among women in the world. Approximately 70% of breast tumours express the estrogen receptor alpha (ERa) and are considered hormone-responsive. Endocrine therapies have long been the treatment of choice. However, the estrogen- like agonist effect and development of resistance of the available selective estrogen receptor modulator such as tamoxifen require developing new treatments that act through different mechanisms. The objective of our study is to design tools that can help to understand the molecular mechanisms involved in ligand-dependent modulation or degradation of ERa. We selected a set of anti-estrogens with different structures and compared their effect on: 1. ERa degradation. 2. Intra-cellular localisation of ERa. 3. Regulation of transcription of ERa- endogenous target genes. 4. Regulation of transcription in the mutants of ERa. Using this mechanistic study we could classify the tested anti-estrogens into three groups based on their function: SERM, SERD and a new group for EM652. SERM (selective estrogen receptor modulator) include compounds such as OH-tamoxifen and RU39411, that stabilise ERa, that re-localize ERa into the nucleus upon binding, that increase transcriptional activity in mutants affecting the recruitment of cofactors or the binding of their side chain and that lack inhibitory capacities of the basal expression of endogenous genes. SERD (selective estrogen receptor modulator) include compounds such as ICI182580 or RU58668, that induce nuclear proteasome-dependent degradation ERalpha which occur in large nuclear foci that colocalize with the proteasome and that inhibit basal gene expression of the endogenous progesterone receptor gene (PGR). Finally, EM652 was found to affect ER degradation and localisation similarly to SERM but inhibited basal gene expression of the endogenous PGR.
Book Synopsis Adjuvant Therapy for Breast Cancer by : Monica Castiglione
Download or read book Adjuvant Therapy for Breast Cancer written by Monica Castiglione and published by Springer Science & Business Media. This book was released on 2009-07-11 with total page 483 pages. Available in PDF, EPUB and Kindle. Book excerpt: Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Book Synopsis HER2-Positive Breast Cancer by : Sara Hurvitz
Download or read book HER2-Positive Breast Cancer written by Sara Hurvitz and published by Elsevier Health Sciences. This book was released on 2018-07-26 with total page 264 pages. Available in PDF, EPUB and Kindle. Book excerpt: Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Book Synopsis Estrogen Receptors in Human Breast Cancer by : William L. McGuire
Download or read book Estrogen Receptors in Human Breast Cancer written by William L. McGuire and published by . This book was released on 1975 with total page 308 pages. Available in PDF, EPUB and Kindle. Book excerpt:
